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and for whom long-term survival was expected.6,7 These
limitations suggest that caution should be exercised in
extrapolating the results of the randomized trials to all
patients and surgeons. 
The Health Care Financing Administration (HCFA)
began the Health Care Quality Improvement Program
(HCQIP) in 1992.8 This new initiative changed the focus
of the state-based, HCFA-funded, Peer Review Organi-
zations from individual case review to performance of
quality improvement projects by the use of larger data sets.
Norman Hertzer, on behalf of the joint vascular societies,
approached then HCFA administrator Bruce Vladek in
1994 regarding the need for HCFA to focus attention on
the outcomes of vascular procedures in the Medicare pop-
ulation.9 The initiation of the HCQIP and the effort of
the vascular societies created the background that allowed
the funding of a 10-state project to examine and attempt
to improve the outcomes of CEA in the Medicare popula-
tion. This report details the results of the baseline data col-
lection from this project.
METHODS
A random sample of 10,561 CEA procedures
(International Classification of Diseases, Ninth Revision,
Clinical Modification [ICD-9-CM] procedure code of
38.12—endarterectomy of vessels of head and neck) per-
The efficacy of carotid endarterectomy (CEA) in
stroke prevention for patients with symptomatic and
asymptomatic carotid stenosis has been well established
in randomized trials.1-5 However, the therapeutic index
is narrow, especially for patients who are asymptomatic.
The randomized trials required each participating sur-
geon to have a proven track record of low morbid-
ity/mortality for CEA.6,7 The trials also limited entry to
patients who were thought to be at low operative risk
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Objectives: The purpose of this study was to describe variation in utilization, care processes, and outcomes for carotid
endarterectomy (CEA) procedures in 10 states. 
Methods: We reviewed the medical records of Medicare patients who underwent 10,561 CEA procedures between June
1, 1995, and May 31, 1996, in 10 different states to determine indications, care processes, and outcomes. This study
also included medical record review of hospital readmissions within 30 days of the procedure and identification of out-
of-hospital deaths from the Medicare beneficiary files. 
Results: Utilization rates of CEA varied from 25.7 to 38.4 procedures per 10,000 Medicare beneficiaries among states.
The overall combined event rate (30-day stroke or mortality) was 5.2% for primary CEA alone (n = 9945). The mor-
tality rate was 1.5%, and the nonfatal stroke rate was 3.7%. Combined event rates (CEA alone) by surgical indication
were 7.7% for stroke (n = 1037), 7.4% for transient ischemic attack (n = 1304), 5.3% for nonspecific symptoms (n =
3713), and 3.7% for asymptomatic patients (n = 3891). The combined event rates (CEA alone) among states ranged
from 4.1% to 7.7% with the event rates in asymptomatic patients ranging from 2.3% to 6.7%. In a multivariate analy-
sis (correcting for indication), the use of preoperative antiplatelet agents (odds ratio [OR], 0.70), intraoperative
heparin (OR, 0.49), and patch angioplasty (OR, 0.73) was significantly associated with lower combined event rates.
There were significant differences among states in the use of preoperative antiplatelet therapy (range, 56%-70%) and
patch angioplasty (range, 11%-49%). Combined event rates for repeat procedures (n = 380) and CEA combined with
coronary artery bypass grafting (n = 236) were 6.3% and 17.4%, respectively.
Conclusions: The striking variation among states suggests that there is room for improvement in the utilization, care
processes, and outcomes of CEA. All surgeons performing CEA should participate in outcome assessment and adopt
protocols that include the routine administration of antiplatelet agents preoperatively, the use of heparin intraopera-
tively, and patch angioplasty of the endarterectomy site. (J Vasc Surg 2001;33:227-35.) 
formed on patients with discharge dates between June 1,
1995, and May 31, 1996, was identified with the
Medicare Provider Analysis and Review (MEDPAR) Part
A claims files from Arkansas, Georgia, Illinois, Indiana,
Iowa, Kentucky, Michigan, Nebraska, Ohio, and
Oklahoma. Patients eligible for Medicare include all
patients 65 years and older, patients with total disability,
and those who have chronic renal failure requiring dialy-
sis. The cases identified for further analysis were from a
universe of 28,083 CEA discharges during that time
period in the 10 states. The sampling strategy was
designed to obtain an adequate number of cases from each
of the states, based on a power calculation with an esti-
mated frequency of combined events (stroke or mortality)
of 6% with a 95% CI and an error of ± 1.5%. A 50% over-
sampling of the calculated individual state samples except
Iowa and Nebraska, which had 100% of cases selected
because of ongoing CEA quality improvement projects,
resulted in a sampling fraction that varied from 0.2 to 1.0
(Appendix I). The smallest individual state sample was 816
procedures, and the largest was 1314 procedures. The
MEDPAR files were also used to identify any hospital
admission that occurred for the beneficiaries in the CEA
sample within 30 days of the discharge date of the primary
admission. Records from any of these hospitalizations with
any admitting or discharge diagnosis code suggesting a
cerebrovascular accident (ICD-9-CM codes 430-438
[cerebrovascular disease]; 784.3 [aphasia]; 784.5 [dyspha-
sia]; 342 [hemiplegia]; and 344 [paralysis]) were
reviewed. The Medicare Enrollment Database was used to
identify deaths that occurred within 30 days of the proce-
dure to capture any deaths that occurred without an asso-
ciated hospital admission.
Data collection. Requests for copies of the entire
medical record for the primary admission and any read-
missions were sent to the hospitals. Compliance with these
requests is mandated by federal statute as part of partici-
pation in the Medicare program. The costs associated with
copying and mailing medical records were reimbursed to
the institution. A data collection tool was created for med-
ical record abstraction by trained abstractors.
Each medical record was comprehensively reviewed to
determine patient demographics, the indication for the
procedure, perioperative care processes, and postoperative
outcomes. The records were reviewed initially by trained
abstractors at a HCFA Clinical Data Abstraction Center
(DynKePRO, York, Pa). Data were abstracted from med-
ical records directly into a computerized data entry system
with an on-line edit check and data definitions to improve
accuracy of data collection.
An extensive effort was made to validate the abstrac-
tion process with respect to identification and classification
(major vs minor stroke) of adverse outcomes. The medical
records of all patients identified as having postoperative
strokes after the initial chart abstraction were indepen-
dently rereviewed by two clinicians with expertise in
stroke. A subset of patients classified by the chart abstrac-
tors as having no postoperative stroke were subjected to
the same clinician validation process to determine if any
postoperative strokes were missed during chart abstrac-
tion. This sensitivity validation subset (n = 356) was cho-
sen on the basis of administrative characteristics (hospital
length of stay > 5 days, discharge codes suggesting post-
operative neurologic complications, and discharges other
than to home) that had been shown to be associated with
postoperative strokes. The results presented reflect the val-
idated data.
Definitions. Indications for CEA were classified into
four mutually exclusive categories. Patients were consid-
ered to have stroke as the indication for the procedure only
if they had documented ipsilateral hemispheric symptoms
that persisted for more than 24 hours within 90 days
before the procedure. Similarly, patients were considered
to have transient ischemic attack (TIA) as the indication
only if transient (< 24 hours) ipsilateral hemispheric symp-
toms occurred within 90 days before the procedure.
Patients were considered to be asymptomatic only if there
was no history at any time before the procedure of cere-
brovascular symptoms or events in either the anterior or
posterior circulations. All other patients (eg, those with
remote ipsilateral symptoms, global or vertebrobasilar
symptoms, contralateral hemispheric symptoms) were
classified in a nonspecific category. These definitions were
used to create relatively clean stroke, TIA, and asympto-
matic indication groups with high reproducibility, given
the limitations of retrospective medical record review. 
CEA procedures were classified into three procedure
groups. CEA with coronary artery bypass grafting (CABG)
included patients who had both a CEA and CABG during
the same operative episode. CEA reoperation was used for
patients who had a prior ipsilateral CEA. All other patients
were included in a CEA-alone group. Preoperative
antiplatelet therapy was defined as aspirin or ticlopidine
that was given to the patient within 2 days before or on
the day of the procedure (but before the procedure). 
For the purpose of outcome classification, a postopera-
tive stroke was considered to have occurred if any new or
worsening central nervous system deficit developed during
the postoperative period and persisted for more than 24
hours. Postoperative strokes were classified as major or
minor by looking at a point in time 5 days after the stroke
or at hospital discharge, whichever occurred sooner. If the
patient had a new persistent deficit that resulted in a need
for assistance with ambulation or eating or had significant
difficulty with speaking, the patient was considered to
have had a major stroke. Patients without disability at 5
days after the event were considered to have had a minor
stroke. These relatively simple definitions allowed for
reproducible classification by abstractors using informa-
tion typically available in the medical record. Deaths were
considered stroke related if the death was associated with a
major stroke. If there was no evidence of major stroke
associated with the death, the death was classified as non-
stroke related.
Data analysis. We examined simple descriptive statis-
tics for the processes and outcomes of CEA care. We
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tested for the significance of the difference between each
state and the aggregate rates in processes with PROC
LOGISTIC and PROC CATMOD (Version 6.12; SAS
Institute, Cary, NC).
To examine the relative impact of different processes
of care on CEA outcomes in the CEA-alone subgroup, we
first evaluated each process as an independent variable.
Each process was examined by means of a multivariate
logistic regression model with the combined event rate as
the dependent variable to account for the effect of indica-
tion. The independent variables in each model were
dichotomous variables representing the process and each
indication. PROC LOGISTIC (Version 6.12; SAS
Institute) was used to compute the Wald statistics. A sim-
ilar analysis was performed to compare each state’s rates
for outcomes (ie, stroke or mortality rate) with the aggre-
gate rate. In this analysis, the process variable was replaced
with a dichotomous variable indicating the state.
The counts of the Medicare population for each of the
10 states were obtained from the HCFA Web site
(http://www.hcfa.gov/stats/histenr.htm). The number
of CEA procedures per 10,000 Medicare beneficiaries by
indication was extrapolated from those counts, the CEA
universe in the state, the sampling fraction, and the
observed indication fraction in each state sample.
Statistically significant variation from the aggregate was
determined with the Mantel-Haenszel χ2 test with one
degree of freedom (Centers for Disease Control and
Prevention’s Epi Info, Version 6).
The variation in indication type and process utilization
was analyzed through several univariate models with the
indication or process as the dependent variable and a cat-
egoric variable with a different value for each state as the
independent variable. PROC CATMOD (Version 6.12;
SAS Institute) was used to analyze the models.
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RESULTS
The number and type of procedures in the state sam-
ples as well as patient age, sex, and indication for the pro-
cedure are provided in Appendix II. The 10,561
procedures in the 10-state sample were performed in
10,030 patients. The patients’ ages ranged from 39 to 95
years; 4.9% of patients were younger than 65 and 19%
were 80 and older. The median length of stay (including
day of discharge) was 4 days with the median postopera-
tive length of stay of 2 days. 
Care process information for the statewide samples for
the CEA-alone procedures is presented in Appendix III.
Preoperative arteriograms were documented in 72%.
Preoperative aspirin or ticlopidine administration was docu-
mented in 62%. Heparin was administered intraoperatively in
98.6% of procedures and was reversed in 55%. The procedure
was performed with patients under local or regional anesthe-
sia in 10% of cases, and routine shunting (no monitoring doc-
umented) was used in 50%. The procedure was performed
without cerebral monitoring and without shunting in 19%.
Patch angioplasty was used in 29% of cases with 74% of the
patches being prosthetic. Some form of intraoperative, pos-
tendarterectomy assessment of the operative site with B-
mode ultrasound imaging/duplex, continuous wave Doppler
scan, or angiography was documented in 29% of cases.
Aggregate outcome data by procedural category are
displayed in Fig 1. Detailed procedural outcome data
including stratification by state and indication category are
available in Appendix IV. The 30-day combined event
(stroke or mortality) rate for the CEA-alone patients in the
10-state sample was 5.2%. The mortality rate was 1.5%, and
the nonfatal stroke rate was 3.7%. The combined event rate
was 7.7% in patients with prior stroke, 7.4% in patients with
preexisting TIAs, 5.3% in patients with nonspecific symp-
toms, and 3.7% in asymptomatic patients. Combined event
Fig 1. Combined event rates (30-day stroke or mortality) and mortality rates for 10-state aggregate for each procedure category (CEA
alone [n = 9945), CEA/CABG [n = 236], and CEA redo [n = 380]) and CEA-alone indication subsets (TIA/stroke [n = 2341], non-
specific [n = 3713] and asymptomatic [n = 3891]). CABG, Coronary artery bypass grafting; CEA, carotid endarterectomy; TIA, tran-
sient ischemic attack.
rates varied significantly (P < .005), stratified by indication
except for stroke versus TIA. Other complications included
postoperative hemorrhage requiring a return to the operat-
ing room in 1.8%, cranial nerve injury in 2.0%, and hyper-
perfusion syndrome in 0.1%.
The 10-state, 30-day, combined event rate for the
patients undergoing CEA/CABG was 17.4% (P < .001 vs
CEA alone) with a mortality rate of 6.4% and a nonfatal
stroke rate of 11.0%. Stroke and TIA were the indications
for operation in only 12% of the patients undergoing CEA
and CABG, and 55% were completely asymptomatic. The
stroke/mortality rate in those patients undergoing CEA
reoperation was 6.3% (P = not significant vs CEA alone),
with the mortality rate being 2.1% and the nonfatal stroke
rate, 4.2%.
There was significant variation in CEA utilization,
indications, care processes, and outcomes among states.
The number of CEAs performed in a state expressed per
10,000 Medicare beneficiaries ranged from a low of 25.7
in Illinois to a high of 38.4 in Michigan (Appendix I). The
proportion of the procedures performed on asymptomatic
patients ranged from 35% to 45% (Appendix II). The over-
all combined event rate varied from 4.1% to 7.7% among
states (Fig 2). The individual state combined event rate in
patients with ipsilateral hemispheric symptoms (stroke or
TIA) ranged from a low of 4.3% to a high of 15.7% (Fig
3). The combined event rate in asymptomatic patients var-
ied from 2.3% to 6.7% (Fig 4). Process variation among
states (Appendix III) included preoperative antiplatelet
use (56%-70%), heparin reversal (40%-68%), routine
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Fig 2. Combined event rates (30-day stroke or mortality) and mortality rates for CEA-alone procedures (all indications) by state
(Arkansas [n = 770], Georgia [n = 958], Illinois [n = 1064], Indiana [n = 1026], Iowa [n = 1265], Kentucky [n = 892], Michigan [n
= 1141], Nebraska [n = 865], Ohio [n = 1143], and Oklahoma [n = 821]). Asterisk indicates significantly different from mean P < .05.
Fig 3. Combined event rates (30-day stroke or mortality) and mortality rates for CEA-alone procedures (TIA/stroke indication only)
by state (Arkansas [n = 184], Georgia [n = 218], Illinois [n = 279], Indiana [n = 230], Iowa [n = 312], Kentucky [n = 207], Michigan
[n = 247], Nebraska [n = 240], Ohio [n = 246], and Oklahoma [n = 178]). Asterisk indicates significantly different from mean P < .05.
shunting (23%-68%), no shunt and absent cerebral perfu-
sion monitoring (10%-28%), and patching (11%-49%) (Fig
5). Also, in an analysis (correcting for indication) of the
multistate CEA alone sample, the preoperative administra-
tion of aspirin or ticlopidine (30% risk reduction), the
intraoperative use of heparin (51% risk reduction), and
patching (27% risk reduction) were all associated with sig-
nificantly lower combined event rates (Table). 
DISCUSSION
The number of procedures in our study is more than
five times larger than any previously reported community-
wide, medical record review of CEA procedures (individ-
ual reports summarized in Appendix V).10-21 Medical
record review is necessary to determine the indication for
the procedure, to determine care processes associated with
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the procedure, and to accurately capture complications.
The Medicare databases also allowed us to identify hospi-
tal readmissions (regardless of whether the readmission
occurred at the same hospital as the procedure) and out-
of-hospital deaths. The only events missed in calculating
30-day event rates would be nonfatal neurologic events
occurring after discharge from the procedural admission
that did not result in another hospital admission.
Administrative databases (individual reports are sum-
marized in Appendix VI) avoid the resource intensive
process of medical record review and can contain attrac-
tively large numbers, but uniformly lack accurate informa-
tion about indication for the procedure and postoperative
complications other than death.22-33 Given the observed
variation in indication for CEA and the significant differ-
ences in outcome based on indication, we do not think
Fig 4. Combined event rates (30-day stroke or mortality) and mortality rates for CEA-alone procedures (asymptomatic indication only)
by state (Arkansas [n = 284], Georgia [n = 422], Illinois [n = 406], Indiana [n = 394], Iowa [n = 512], Kentucky [n = 356], Michigan
[n = 438], Nebraska [n = 317], Ohio [n = 473], Oklahoma [n = 289]). Asterisk indicates significantly different from mean P < .05.
Fig 5. Use of patch angioplasty for CEA-alone procedures (all indications) by state. Asterisk indicates significantly different from mean P <.05.
that administrative data can be used for valid outcome
comparisons. Administrative databases are also devoid of
process information. Prospective registries (individual
reports summarized in Appendix VII) have also been used
to document the community-wide outcomes for
CEA.21,34-39 However, registries usually represent the
results of selected providers (eg, vascular societies, volun-
teers) and often do not represent the community as a
whole. Both administrative databases and registries are
subject to reporting bias.
Common definitions of indication and outcomes are
important if comparisons are to be made between studies.
We chose our definitions of TIA, stroke, and asympto-
matic so that comparisons could be made to the bench-
marks achieved in the randomized trials. Our definition of
asymptomatic is somewhat stricter than that used in the
Asymptomatic Carotid Atherosclerosis Study (ACAS), in
that we included patients in the asymptomatic category
only if there was no prior history of events in any cerebral
distribution (including the contralateral hemisphere). The
value of stratifying patients (eg, those with remote ipsilat-
eral hemispheric symptoms, contralateral symptoms, ver-
tebrobasilar or global ischemia) not meeting the strict
symptomatic or asymptomatic definition in a nonspecific
category was confirmed by the intermediate combined
event rate observed in this group of patients (TIA/stroke
indication, 7.5%; nonspecific symptoms, 5.3%; asympto-
matic, 3.7%).
It is encouraging that the overall Medicare patient
stroke or mortality rate of 7.5% for symptomatic patients
observed in the 10-state sample was only slightly higher
than the 6.5% rate reported in the North American
Symptomatic Carotid Endarterectomy Trial (NASCET)
study (combined reports).40 The higher morbidity/mor-
tality rate could easily be explained by the older age of the
population in this report (19% ≥ 80 years), compared with
the NASCET population that excluded patients older than
79. The retrospective medical record review method used
in this study, however, would not be as sensitive in identi-
fying all neurologic events as would the prospective,
mandatory, postoperative neurologic examinations per-
formed as part of the NASCET.
The overall observed rate of combined events for
asymptomatic patients (3.7%) is more troublesome given
the 1.5% rate (excluding strokes included in the intention to
treat analysis that occurred preoperatively) observed in the
ACAS and the narrow therapeutic benefit of surgical versus
medical therapy for asymptomatic patients.41 It would be
inappropriate to justify the higher rate in the older Medicare
population, because selecting patients with low operative
risk and longer expected survival is essential in identifying
asymptomatic patients likely to benefit from CEA.
The relatively high stroke or mortality rate (17.4%)
observed in the patients who underwent combined
CEA/CABG indicates that caution should be exercised in
recommending the combined approach. The observed
stroke/mortality rate for CEA/CABG is especially discon-
certing given the fact that more than half of the patients
had no prior neurologic symptoms or events. The
observed rate in the current study is higher than the rates
identified in many single-institution reports.42 In contrast,
the overall combined event rate of 6.3% in patients under-
going repeat procedures was not significantly different
from the event rate in patients undergoing primary (CEA-
alone) procedures. 
The most cogent observation in this study indicating a
need for quality improvement is the striking variation in uti-
lization, process, and outcomes among the states. Variation
in the utilization of CEA has been described previously.43,44
This is the first large scale report documenting the regional
variation stratified by indication for the procedure. It is not
surprising that most of the variation occurred in patients
who were asymptomatic or had nonspecific symptoms. The
50% higher CEA utilization rate in Michigan versus Illinois
is hard to explain or justify. To put this in perspective, if the
Michigan utilization rate was applied to Illinois, more than
2000 additional Medicare patients would have undergone
CEA in Illinois during the 1-year study period. Significant
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Process/outcome relationship (CEA alone—corrected for indication)
Predictor of stroke or mortality P value OR 95% CI on OR
Preoperative angiography .06 1.22 0.99-1.51
Preoperative aspirin/ticlopidine* .0001 0.70 0.59-0.84
Local/regional anesthesia .4 0.88 0.65-1.20
Use of heparin* .01 0.49 0.28-0.87
Reversal of heparin .3 0.91 0.76-1.10
Use of patch* .003 0.73 0.59-0.90
Use of vein patch .8 1.03 0.74-1.44
Use of prosthetic patch* .001 0.67 0.52-0.85
Use of EEG .4 1.10 0.87-1.38
Monitoring of back pressure .7 0.93 0.63-1.37
Shunt, no monitoring .09 0.86 0.72-1.03
No monitoring, no shunt .09 1.20 0.97-1.49
Postreconstruction assessment .9 1.02 0.84-1.24
*Statistically significant predictor of stroke or mortality at P level < .05, while controlling for indication.
CEA, Carotid endarterectomy; EEG, electroencephalogram; OR, odds ratio.
variation also occurred in all of the care processes examined
and likely reflects uncertainty about the utility of some of the
processes. The rate of patching in Ohio (49%) was more than
four times higher than the patching rate in Iowa (11%). 
The observed variation in outcomes makes the
strongest case for the need for quality improvement. The
stroke or mortality rates in asymptomatic patients
observed in Arkansas (6.7%) and Oklahoma (6.6%) were
almost three times higher than the rate in Indiana (2.3%).
If the observed rates in Arkansas and Oklahoma had been
the surgical combined event rate in the ACAS, the trial
certainly would not have indicated surgical benefit. If we
extrapolate the observed indication and outcome results
from this 10-state study to the entire US Medicare popu-
lation and compare that prediction with an extrapolation
using benchmark outcomes (NASCET, ACAS, best state
observed rate in this study for nonspecific), more than 500
fewer deaths and 1000 fewer nonfatal strokes after CEA
would have occurred in 1996. 
The relationships observed between certain processes
and outcomes are an equally important finding in this study.
The significant risk reduction associated with preoperative
antiplatelet drug administration and patching confirms the
findings of small randomized trials indicating the benefit of
these modalities.45-48 Our results did not suggest an advan-
tage of the use of vein over prosthetic patch material. We can
extrapolate using the observed odds ratios for the three
processes that we found were associated with better out-
comes to predict hypothetical outcomes if the three
processes had been used in all procedures. Eighteen percent
of the procedures in our sample were associated with preop-
erative antiplatelet therapy, intraoperative heparin, and
patching. The combined stroke or mortality rate for these
procedures was 3.5%. We created a logistic regression model
(controlling for indication) with the assumption that all sur-
geons used all three processes. On the basis of this model, we
would predict 2800 fewer strokes or deaths after CEA in the
US Medicare population in 1996 than would be predicted
by extrapolating with the observed outcomes in this study.
Caution must always be observed in using associations from
a retrospective, observational study such as in the current
study when establishing a clear cause and effect relationship.
However, it seems likely that any bias introduced in an
uncontrolled study would be that  preoperative antiplatelet
therapy and patching would be associated with procedures
with predicted poorer outcomes. Symptomatic patients
would seem more likely to be receiving antiplatelet agents
preoperatively, and surgeons are more likely to patch a prob-
lematic endarterectomy site. Therefore, we think that the
findings in this study and the cited randomized trial evidence
justify a solid recommendation for universal administration
of preoperative antiplatelet therapy and patching of the
endarterectomy site.
CONCLUSIONS
Valid CEA outcome comparisons require stratification
by indication for the procedure and the use of common def-
initions for indication and adverse outcomes. We suggest
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that three indication strata (TIA/stroke, asymptomatic, non-
specific) with definitions similar to those used in this study
become the standard for future CEA outcome reporting. We
found that the community-wide CEA outcomes for sympto-
matic Medicare patients were similar to those achieved in the
NASCET. However, the combined event rates for asympto-
matic patients were more than two times those observed in
the ACAS. The combined event rates in patients undergoing
CEA/CABG were unacceptably high. There was a striking
variation in the utilization, care processes, and outcomes of
CEA among the 10 states in this study, which indicates the
potential and the need for quality improvement. We think
that all surgeons performing CEA should participate in stan-
dardized outcome assessment and adopt protocols that
include the routine administration of antiplatelet therapy
before the procedure, the use of heparin intraoperatively, and
closure of the endarterectomy site with a patch.
The analyses on which this publication is based were per-
formed under contracts, entitled “Utilization and Quality
Control Peer Review Organization,” sponsored by the
Health Care Financing Administration, Department of
Health and Human Services. This article is a direct result of
the Health Care Quality Improvement Program initiated by
the Health Care Financing Administration, which has
encouraged identification of quality improvement projects
derived from analysis of patterns of care, and therefore,
required no special funding on the part of this Contractor.
Ideas and contributions to the author concerning experience
in engaging with issues presented are welcome.
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Dr Norman R. Hertzer (Cleveland, Ohio). Dr Kresowik and
all of the people working with him on this project have brought
us, and the nation, probably the most refined Medicare dataset
for carotid endarterectomy that has ever been reported. Unlike
most Medicare surveys that are limited to an analysis of crude
postoperative mortality rates, this one enlisted Peer Review
Organizations to collect very specific information concerning pre-
operative indications, intraoperative management, and 30-day
outcomes on the basis of an individual audit of over 10,000
patients in 10 states.
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been able to stand up here and tell you that regional anesthesia
was associated with better outcomes, but that was not the case.
We did look at all those processes. For example, almost 20% of the
cases received no monitoring and no shunt, and we did not find
significantly poorer outcomes in that subgroup. There was a
trend, but not a significant association. There were only three
processes (heparin use, antiplatelet therapy, and patching) that
were associated with significant risk reductions.
Dr Jack L. Cronenwett (Lebanon, NH). I am very excited
about these data, which are extraordinarily powerful.
My question relates to whether you had an opportunity to
correlate these outcomes with volume, either by hospital or by
surgeon. Several studies have shown that volume outcome is par-
ticularly important in carotid surgery, and I wonder if that
explains in part some of the variation that you observed?
Dr Kresowik. It’s a very important question. When we started
this project, we wanted to focus on quality improvement, and
some of those kind of issues become very political. This project is
based on review of the inpatient records, and one of the issues is
that it can be very difficult to determine who was the operating
surgeon. We have to cross-reference to physician claims. The sur-
gical bill, as you know, is under Part B of Medicare, and this is a
very large dataset. We are going to link all these patients to the
surgeon that billed for the procedure, and then we can do the
kind of analysis you requested. We also hope not only to link vol-
ume to outcome, but also to examine the impact of training. We
can use the American Board of Surgery database and at least use
board certification in a certain area, whether it be vascular, gen-
eral surgery, cardiothoracic, or neurosurgery, as a surrogate for
training. So we do want to continue this work, and we’re certainly
going to be looking at those questions.
Dr Ramon Berguer (Detroit, Mich). My congratulations for
your excellent presentation. I just have curiosity about an intrigu-
ing group you mentioned in your factors of risk analysis: the
patients that were operated on without systemic heparinization. I
can’t quite understand. How many of those patients were in the
series, and do you have any idea how relevant this was to the inci-
dence of reported stroke?
Dr Kresowik. Yes, it’s a very small number. I think the overall
number was 98.6% who were operated on using heparin, which is
why I didn’t focus on heparin use as a process with a lot of room
for improvement. Even with the small numbers of patients who
did not receive heparin, there was a significant difference in out-
come. The risk reduction with the use of heparin was 50%.
Dr Robert W. Hobson II (Newark, NJ). Excuse me for
extending the discussion, but I can’t believe this audience hasn’t
responded to your comments about the combined CABG and
endarterectomy cases with an over 17% 30-day stroke and death
rate. Did your analysis give you any insight as to the etiology of
the strokes occurring in that group? Do you have any insight as
to who did the procedures, what their technical competency was,
and why in the world the rate was so extraordinarily high?
Dr Kresowik. I am unable to provide more insight. Again this
is the subgroup consisting of a sample from 10 states. There were
236 patients who underwent the combined procedure, so it’s not
a small number. But it’s a small number from each state, and we
didn’t analyze it by surgeon. Only 12% of that group actually had
indications of TIA or stroke, so the vast majority of patients were
asymptomatic or had only nonspecific symptoms preoperatively,
which is really disconcerting in terms of the actual morbidity that
we found.
It is a remarkable study not only because it clearly tells us how
successful we have been with carotid endarterectomy, but more
important because it shows us with big, significant numbers how
we can make it an even safer operation in the future. Should
patients receive preoperative antiplatelet therapy? Yes, they should,
because it reduces the stroke and/or mortality rate by 30%. Is
carotid patching really necessary? Well, apparently so, because it
also reduces the combined complication rate by 27%. Must the
results of carotid endarterectomy be audited in every hospital?
Absolutely, because if the utilization and risk can be three times
higher in one state than in another, you can imagine the differ-
ences that exist between one hospital and another, especially if you
consider all of the variables associated with low and high volumes.
I have one question for Dr Kresowik that should be of inter-
est to the audience here and eventually in the Journal of Vascular
Surgery. It was my understanding when this project was imple-
mented in 1995 that the retrospective chart review would be used
to establish baseline parameters and then would be followed by 3
years of prospective outcome assessment to determine whether
the knowledge generated by the chart review, or perhaps just the
surveillance itself, might somehow improve results. The problem
that we encountered in Ohio is that, while the state PRO can
invite hospitals to participate in prospective assessment, it cannot
force them to participate even if it seems to be in the public inter-
est for them to do so. In this regard, what has happened with
Phase II of this project and will it be conducted at all?
Finally, I just want to remind you that HCFA initiated this
project largely at the suggestion of these two societies. Therefore,
I think all of us should be proud of this study and the job that Dr
Kresowik and his team have done with it.
Dr Timothy F. Kresowik. Thanks very much, Norm. I think
we also owe a personal debt of gratitude to Dr Hertzer, who went
to HCFA on our behalf to encourage these kinds of outcome
studies. I think his efforts did us all a favor in terms of having
HCFA personnel see vascular surgeons as interested in something
more than just how much we are paid. I don’t mean to diminish
at all the importance of our continued work to get our underval-
ued services properly reimbursed.
To answer your question, we do have an ongoing project. We
have a similar sample of approximately the same number of
patients with data collection underway now. The remeasurement
period includes medical records from June 1998 to May 1999.
There have been efforts in a number of the states to improve their
outcomes. We presented our results from Iowa last fall at the
Midwest Vascular meeting, and they were published in the May
Journal of Vascular Surgery. In that report we found a decrease in
the stroke mortality rate in 14 hospitals, from 6.5% in 1994 to
1.8% in 1998. Those 14 hospitals perform about 75% of the
CEAs done in our state. I hope to find similar results in some of
the other states when we do the remeasurement.
Dr David C. Brewster (Boston, Mass). I, too, would congrat-
ulate Dr Kresowik and his colleagues. I think this is a very impor-
tant study and really illustrates the potential power of such careful
outcome analysis to influence and hopefully improve practice.
Did your data, Tim, have any findings relative to several
other important procedural variables, such as whether regional
block or general anesthesia was used, whether or not EEG mon-
itoring was employed, or if shunting was utilized? Did any of
these variables correlate with outcome in any way?
Dr Kresowik. Thanks, David. As a person who does the pro-
cedure under regional anesthesia, I would have loved to have
